Clinical

Dataset Information

0

Phase II study of bevacizumab combined with oral leucovorin plus UFT for elderly patients with metastatic colorectal cancer.


ABSTRACT: Interventions: Bevacizumab 5mg/kg is administered intravenous injection on day 1,15. UFT 300mg/m2/day and LV 75mg/body/day is administered orally for 21 days every 28 days. Primary outcome(s): Progression-free survival Study Design: Single arm Non-randomized

DISEASE(S): Advanced And Recurrent Colorectal Cancer

PROVIDER: 2618974 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2618906 | ecrin-mdr-crc
| 2624363 | ecrin-mdr-crc
| 2623111 | ecrin-mdr-crc
| 2622557 | ecrin-mdr-crc
| 2631332 | ecrin-mdr-crc
| 2614185 | ecrin-mdr-crc
| 2618840 | ecrin-mdr-crc
| 2617052 | ecrin-mdr-crc
| 2616452 | ecrin-mdr-crc
| 2609499 | ecrin-mdr-crc